Published in the Lancet Oncology, this study from the Mayo Clinic group reported outcomes of 39 patients with WHO grade 4 glioblastoma treated with concurrent hypofractionated PBT (35-40 Gy equivalents in five or ten fractions) and chemotherapy.

Median overall survival was 13.1 months. Grade 3 adverse events were CNS necrosis (10%) and thrombocytopenia (3%). There was no grade 4 or greater adverse events. These treatment results were improved compared to historical data.

The authors have opened a phase 2 study (NCT05781321) investigating this regimen versus standard-of-care treatment in adults of any age with newly diagnosed glioblastoma.